Previous 10 | Next 10 |
ICONIC Phase 3 clinical program initiation in adults with moderate to severe plaque psoriasis ANTHEM Phase 2b initiation in ulcerative colitis Company is eligible to receive next two milestone payments for a total of $60M NEWARK, CA / ACCESSWIRE / October 9, 2023 / Protagonist Ther...
2023-09-22 15:35:32 ET Summary Protagonist Therapeutics, Inc.'s oral IL-23 drug for psoriasis, JNJ-2113, must show non-inferior efficacy to Johnson & Johnson's injectable Tremfya before further development. JNJ-2113 is the only oral IL-23 targeting molecule in development, but...
2023-09-22 10:15:25 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal , optimism in the b...
NEWARK, CA / ACCESSWIRE / September 5, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in fireside chat presentations and host one-on-one meetings at the Well...
2023-09-04 02:56:19 ET Summary Protagonist Therapeutics focuses on peptide-based drugs, primarily rusfertide, which is undergoing a Phase 3 trial for polycythemia vera. Financially, PTGX is robust with $313.4M in assets and a cash runway of ~31 months; rusfertide shows significant...
2023-08-09 14:44:26 ET Summary Protagonist Therapeutics, Inc. is progressing with the use of its drug rusfertide for the treatment of polycythemia vera in a phase 3 study. The company expects to complete enrollment of the VERIFY study by Q1 2024 and release results in 2024. Pr...
Estimated cash runway now extended through Q1 2026 NEWARK, CA / ACCESSWIRE / August 9, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced it has received approximately $34.4 million in proceeds from the exercise of warrants to purchase 2.75 million...
2023-08-03 17:33:52 ET Protagonist press release ( NASDAQ: PTGX ): Q2 GAAP EPS of -$0.68 misses by $0.03 . Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of June 30, 2023, were $313.4 million. For further det...
Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first and only IL-23 receptor antagonist oral peptide drug candidate for the treatment of moderate-to-severe plaque psoriasis, presented at the World Congress of Dermatology. JNJ-2113 now advances ...
2023-07-05 08:15:30 ET Impel Pharmaceuticals ( IMPL ) +36% . Wolfspeed ( WOLF ) +18% enter 10-year silicon carbide wafer supply agreement. Nocera ( NCRA ) +12% . Digital World Acquisition ( DWAC ) +10% reaches in-principle settleme...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 75.8% to $0.0457 on volume of 1,196,767,473 shares NVIDIA Corporation (NVDA) fell 6.8% to $114.25 on volume of 316,196,296 shares Sangamo Therapeutics Inc. (SGMO) rose 39.5% to $0.56 on volume of 261...
NEWARK, CA / ACCESSWIRE / July 22, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the BTIG Virtual Biotechnolog...